Designer molecule kills malarial parasites

A research team from The Australian National University (ANU) and The University of Queensland has designed and made a molecule derived from a human protein that kills the parasite which causes malaria.

Treatments for malaria, a disease that kills a person every 90 seconds, are becoming less effective because of drug resistance and there is a risk to the future control of the disease.

Lead researcher Associate Professor Brendan McMorran from ANU said the team was a step closer to developing a new and effective treatment for malaria.

“We have designed and created a small fragment of a human protein called Platelet factor 4, known as PF4, that can kill the microbial parasite that causes malaria, Plasmodium,” said Dr McMorran from the John Curtin School of Medical Research.

“PF4, which my research group at ANU identified in previous work, is the only human protein known to kill malarial parasites.”

The protein is relatively large and not suited to use as a treatment, so the team copied parts of the protein that are critical for terminating the malarial parasites into a smaller molecule, otherwise known as a peptide.

“We have shown that this peptide kills the parasite in a way that is completely different to how current antimalarial drugs work,” Dr McMorran said.

“This is important because finding new ways to kill the parasite will help us overcome the drug-resistance problems.”

The study involved expertise from several disciplines from the John Curtin School of Medical Research, the ANU Research School of Biology and The Institute for Molecular Bioscience at The University of Queensland.

The researchers tested the peptide’s effectiveness at killing the malarial parasite cultured in human red cells under laboratory conditions.

The team will develop more potent versions of the peptide that can be used as new treatments for malaria.

“To do this, we plan to modify the peptide to include new functions that target other vulnerable parts of the parasite, and make the peptide more suited to being administered to people,” Dr McMorran said.

The research is published in Cell Chemical Biology.

 

FOR INTERVIEW:

Associate Professor Brendan McMorran
John Curtin School of Medical Research
ANU College of Science
M: +61 403 148 799
E: brendan.mcmorran@anu.edu.au

Dr Nicole Lawrence
Institute for Molecular Bioscience
The University of Queensland
M: +61 407 033 708
E: n.lawrence@imb.uq.edu.au

For media assistance, contact Will Wright on +61 2 6100 3486, the ANU media hotline on +612 6125 7979 or email the ANU Media Team at <media@anu.edu.au>.

About The Australian National University

ANU is a world-leading university in Australia’s capital city, Canberra. Our location points to our unique history, ties to the Australian Government and special standing as a resource for the Australian people.

Our focus on research as an asset, and an approach to education, ensures our graduates are in demand the world-over for their abilities to understand, and apply vision and creativity to addressing complex contemporary challenges.

The Australian National University
East Road, Acton
2601 Canberra